Detailled Information

Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986-991. 

This article aims to explore the relationship between MDA and the low disease activity cutoffs of the PASDAS and the CPDAI. Cut-offs for very low disease activity were developed.

This study aimed to validate a cutoff value of PASDAS that defines minimal disease activity (MDA) state, as well as to validate previously defined PASDAS cutoffs for low and high disease activity.

This study aims to compare the performance of the PASDAS, the AMDF, the CPDAI, and the DAPSA in the GO-REVEAL data set. 

GRAPPA and OMERACT met to further the develop a consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).

The PASDAS is a weighted composite in which the greatest weights are placed on both physician and patient global scores, also has contributions from joints, skin, dactylitis, enthesitis, acute‐phase response, and health‐related QOL, all important aspects of disease for patients and physicians.

The following variables were used: patient global VAS (0–100), physician global VAS (0–100), 66 swollen joint count, 68 tender joint count, CRP level (mg/litre), enthesitis (Leeds Enthesitis Score 0-6), tender dactylitis count (score range 0–20), and, finally, the physical component summary (PCS) scale of the Short Form 36 (SF‐36, or SF12) health survey.

A PASDAS score between 0-10 is calculated using a weighted formula. ((0.18 x √Physician global VAS) þ (0.159 x √Patient global VAS)  (0.253 x √SF36  PCS)  (0.101 x LN (Swollen joint count þ 1)) þ (0.048 x LN (Tender joint count þ 1))  (0.23  LN (Leeds Enthesitis Count þ 1))  (0.377 LN (Dactylitis count þ 1))  (0.102 x LN (CRP þ 1)) 2)*1.5